ReviewIntestinal research2017
Second Korean guidelines for the management of ulcerative colitis.
Review in Intestinal research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 78 citations in OpenAlex.
- Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis.The Korean journal of internal medicine · 2022Trial
- Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia: A Randomized, Controlled Trial.Gut and liver · 2018Trial
- Dosing 5-ASA for Ulcerative Colitis: Is the Maximum Optimum?Digestive diseases and sciences · 2026Article
- Ten-Year Trend in 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients with Ulcerative Colitis: An Analysis of Korean Health Insurance Data.Digestive diseases and sciences · 2026Observational
- Comparison of 1-Year Clinical Course in Patients With Newly Diagnosed Inflammatory Bowel Disease Between Vietnam and Korea: A Multinational, Multicenter Retrospective Cohort Study.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- [Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti-Tumor Necrosis Factors].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2024Review
- [Risks of Cancer Associated with Therapeutic Drugs for Inflammatory Bowel Disease].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2024Review
- Article
- Screening for Chemical Characterization and Pharmacological Properties of Different Extracts fromPlants (Basel, Switzerland) · 2023Article
- Treatment of inflammatory bowel disease-Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn's and Colitis meeting.Intestinal research · 2023Article
- Infectious complications in patients with inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 8th Asian Organization for Crohn's and Colitis meeting.Intestinal research · 2023Article
- Factors associated with the prescription of probiotics in patients with inflammatory bowel disease: a cross-sectional study.Journal of Yeungnam medical science · 2023Article
- Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis.Intestinal research · 2023Review
- Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study.Therapeutic advances in gastroenterology · 2023Article
- Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis.The Korean journal of internal medicine · 2022Article
- Physician education can minimize inappropriate steroid use in patients with inflammatory bowel disease: the ACTION study.Intestinal research · 2022Article
- Corticosteroid, a double-edged sword in inflammatory bowel disease management: possibility of reducing corticosteroid use through physician education.Intestinal research · 2022Article
- Identification of useful genes from multiple microarrays for ulcerative colitis diagnosis based on machine learning methods.Scientific reports · 2022Article
- Efficacy of sigmoidoscopy for evaluating disease activity in patients with ulcerative colitis.BMC gastroenterology · 2022Article
- Draft Genome Sequence of Paraclostridium bifermentans subsp.Microbiology resource announcements · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 10 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by a relapsing and remitting course. The direct and indirect costs of the treatment of UC are high, and the quality of life of patients is reduced, especially during exacerbation of the disease. The incidence and prevalence of UC in Korea are still lower than those of Western countries, but have been rapidly increasing during the past decades. Various medical and surgical therapies, including biologics, are currently used for the management of UC. However, many challenging issues exist, which sometimes lead to differences in practice between clinicians. Therefore, the IBD study group of the Korean Association for the Study of Intestinal Diseases established the first Korean guidelines for the management of UC in 2012. This is an update of the first guidelines. It was generally made by the adaptation of several foreign guidelines as was the first edition, and encompasses treatment of active colitis, maintenance of remission, and indication of surgery for UC. The specific recommendations are presented with the quality of evidence and classification of recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.